EICHORCondition: Acute Myeloid Leukemia (AML) in Remission · Sponsor: The First Affiliated Hospital of Soochow University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.
This description comes directly from the study's public registry record.
Suning Chen · +86-13814881746 · chensuning@sina.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology | Suzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05404906